Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 1/20 | 0.42 |
| ▸ | IDH1 | O75874 | 11/20 | 0.42 |
| ▸ | LCK | P06239 | 3/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2638251 | 0.90 | IDH1 (0.51) | CBFBIDH1 | |
| SCHEMBL4848243 | 0.77 | CAMK2D (0.47) | IDH1MAPK14 | |
| SCHEMBL4848233 | 0.77 | CAMK2D (0.47) | IDH1MAPK14 | |
| SCHEMBL3536417 | 0.73 | GSK3B (0.48) | GSK3BSYK | |
| SCHEMBL7022910 | 0.72 | LCK (0.56) | IDH1LCKSYKRPS6KB1 | |
| SCHEMBL3538590 | 0.72 | GSK3B (0.47) | GSK3B | |
| SCHEMBL3541334 | 0.71 | GSK3B (0.48) | GSK3BSYK | |
| SCHEMBL13312982 | 0.71 | GSK3B (0.46) | GSK3BSYK | |
| SCHEMBL3536964 | 0.71 | GSK3B (0.49) | GSK3B | |
| SCHEMBL3534156 | 0.70 | GSK3B (0.48) | GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042880-A1 | NOVEL 4-BENZIMIDAZOL-2-YLPYRIDAZIN-3-ONE DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2009-02-12 | — | — | US | disclosed |
| US-20090042880-A1 | NOVEL 4-BENZIMIDAZOL-2-YLPYRIDAZIN-3-ONE DERIVATIVES | AVENTIS PHARMA S.A. (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042880-A1 | NOVEL 4-BENZIMIDAZOL-2-YLPYRIDAZIN-3-ONE DERIVATIVES | CDK2, CDK1, CDK4 | CBFB 2895/4885IDH1 475/4885LCK 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.